LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Home・Akciju saraksts・United Therapeutics Corp

United Therapeutics Corp

Slēgts

SektorsVeselības aprūpe

532.11 13.11

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

471.31

Max

534.67

Galvenie mērījumi
By Trading Economics
Ienākumi	29M 339M
Pārdošana	900K 800M
P/E Sektora vidējais	17.995 108.767
Peļņas marža	42.364
Darbinieki	1,305
EBITDA	26M 463M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+17.27% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 25. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	2.7B 21B
Iepriekšējā atvēršanas cena	519
Iepriekšējā slēgšanas cena	532.11

Ziņu noskaņojums

By Acuity

17%

83%

23 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

292.345 / 309.245 Atbalsts un pretestība

United Therapeutics Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. febr. 23:07 UTC

Peļņas

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. g. 24. febr. 23:01 UTC

Peļņas

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. g. 24. febr. 22:59 UTC

Peļņas

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026. g. 24. febr. 22:42 UTC

Peļņas

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026. g. 24. febr. 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026. g. 24. febr. 23:46 UTC

Tirgus saruna

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026. g. 24. febr. 23:36 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026. g. 24. febr. 23:30 UTC

Tirgus saruna

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026. g. 24. febr. 23:20 UTC

Tirgus saruna

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026. g. 24. febr. 23:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 24. febr. 23:16 UTC

Peļņas

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026. g. 24. febr. 23:13 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026. g. 24. febr. 23:12 UTC

Peļņas

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026. g. 24. febr. 23:10 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026. g. 24. febr. 23:10 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026. g. 24. febr. 23:08 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026. g. 24. febr. 23:07 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026. g. 24. febr. 22:52 UTC

Peļņas

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. g. 24. febr. 22:46 UTC

Peļņas

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. g. 24. febr. 22:31 UTC

Iegādes, apvienošanās, pārņemšana

Warner Receives New Bid From Paramount -- 3rd Update

2026. g. 24. febr. 22:29 UTC

Peļņas

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026. g. 24. febr. 22:28 UTC

Peļņas

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026. g. 24. febr. 22:27 UTC

Peļņas

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026. g. 24. febr. 22:27 UTC

Peļņas

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026. g. 24. febr. 22:25 UTC

Peļņas

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026. g. 24. febr. 22:24 UTC

Peļņas

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026. g. 24. febr. 22:23 UTC

Peļņas

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026. g. 24. febr. 22:22 UTC

Peļņas

Woolworths Interim Dividend 45 Australian Cents/Share

2026. g. 24. febr. 22:22 UTC

Peļņas

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

2026. g. 24. febr. 22:21 UTC

Peļņas

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Salīdzinājums

Cenas izmaiņa

United Therapeutics Corp Prognoze

Cenas mērķis

By TipRanks

17.27% augšup

Prognoze 12 mēnešiem

Vidējais 555.2 USD 17.27%

Augstākais 645 USD

Zemākais 423 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi United Therapeutics Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam United Therapeutics Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

292.345 / 309.245Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

23 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.